Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes

被引:19
作者
Takami, K
Takeda, N
Nakashima, K
Takami, R
Hayashi, M
Ozeki, S
Yamada, A
Kokubo, Y
Sato, M
Kawachi, S
Sasaki, A
Yasuda, K
机构
[1] Gifu Univ, Sch Med, Dept Internal Med 3, Gifu 5008705, Japan
[2] Kizawa Mem Hosp, Dept Internal Med, Gifu, Japan
[3] Matsunami Gen Hosp, Dept Internal Med, Gifu, Japan
关键词
D O I
10.2337/diacare.25.4.658
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To examine the effects of diet and diet with voglibose or glyburide on abdominal adiposity and metabolic abnormalities in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - A total of 36 Japanese patients with newt), diagnosed type 2 diabetes (50.8 +/- 8.6 years of age, BMI 24.5 +/- 3.5 k g/m(2)) and 273 normal control Subjects were studied, The patients were treated for 3 months with diet alone (30 kcal/kg per day) (n = 15), diet with voglibose (n = 12), or diet with glyburide (11 = 9). The), underwent 75-g oral glucose tolerance testing, assessment of insulin sensitivity (SI), and acute insulin response (AIR) with intravenous glucose tolerance testing based on the minimal model, and measurement of abdominal Visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) by Computed tomography before and after treatment. RESULTS - The diabetic patients had comparable SAT but larger VAT than the control subjects. With a mean weight loss of 2-3 kg, VAT and SAT were decreased similarly in all treatment groups. The VAT-to-SAT ratio was decreased only in the voglibose group. Glycemic control and serum lipid profiles were improved in all groups, Changes in glycemic control after diet were closely correlated with changes in VAT but not with changes in SAT. SI and AIR were unchanged in the diet group but were improved in the voglibose and glyburide groups, CONCLUSIONS - in Japanese patients with newly diagnosed type 2 diabetes who were relatively lean but had excess VAT, diet with or without voglibose or glyburide effectively reduced VAT. Decrease in VAT was closely associated with Improvement of glycemic control with diet. Additional use of voglibose or low-dose glyburide had no detrimental effects on abdominal adiposity and had beneficial effects on SI and AIR.
引用
收藏
页码:658 / 662
页数:5
相关论文
共 19 条
[1]   MECHANISM OF ACTION OF SULFONYLUREAS WITH SPECIAL REFERENCE TO THE EXTRAPANCREATIC EFFECT - AN OVERVIEW [J].
BECKNIELSEN, H ;
HOTHERNIELSEN, O ;
PEDERSEN, O .
DIABETIC MEDICINE, 1988, 5 (07) :613-620
[2]   TOWARD PHYSIOLOGICAL UNDERSTANDING OF GLUCOSE-TOLERANCE - MINIMAL-MODEL APPROACH [J].
BERGMAN, RN .
DIABETES, 1989, 38 (12) :1512-1527
[3]   Visceral adiposity and risk of type 2 diabetes - A prospective study among Japanese Americans [J].
Boyko, EJ ;
Fujimoto, WY ;
Leonetti, DL ;
Newell-Morris, L .
DIABETES CARE, 2000, 23 (04) :465-471
[4]   OBESITY, FAT DISTRIBUTION, AND WEIGHT-GAIN AS RISK-FACTORS FOR CLINICAL DIABETES IN MEN [J].
CHAN, JM ;
RIMM, EB ;
COLDITZ, GA ;
STAMPFER, MJ ;
WILLETT, WC .
DIABETES CARE, 1994, 17 (09) :961-969
[5]   Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians - Analysis of the impact of gender, body fat, physical fitness, and life-style factors [J].
Clausen, JO ;
BorchJohnsen, K ;
Ibsen, H ;
Bergman, RN ;
Hougaard, P ;
Winther, K ;
Pedersen, O .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (05) :1195-1209
[6]   VOGLIBOSE (AO-128) IS AN EFFICIENT ALPHA-GLUCOSIDASE INHIBITOR AND MOBILIZES THE ENDOGENOUS GLP-1 RESERVE [J].
GOKE, B ;
FUDER, H ;
WIECKHORST, G ;
THEISS, U ;
STRIDDE, E ;
LITTKE, T ;
KLEIST, P ;
ARNOLD, R ;
LUCKER, PW .
DIGESTION, 1995, 56 (06) :493-501
[7]   MAGNETIC-RESONANCE-IMAGING USED FOR DETERMINING FAT DISTRIBUTION IN OBESITY AND DIABETES [J].
GRAY, DS ;
FUJIOKA, K ;
COLLETTI, PM ;
KIM, H ;
DEVINE, W ;
CUYEGKENG, T ;
PAPPAS, T .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1991, 54 (04) :623-627
[8]   Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes [J].
Kelly, IE ;
Han, TS ;
Walsh, K ;
Lean, MEJ .
DIABETES CARE, 1999, 22 (02) :288-293
[9]  
KREYMANN B, 1987, LANCET, V2, P1300
[10]  
KVIST H, 1986, INT J OBESITY, V10, P53